Lantheus Announces New Patient Outcomes Data for DEFINITY® to be Presented at the American Society of Echocardiography 2019 Annual Scientific Sessions
Company will also host a scientific symposium and interactive panel discussion focused on enhanced echocardiography
Details for the poster presentation are as follows:
Title:Impact of Contrast Echocardiography on Clinical Outcomes in Critically Ill Patients
Date and Time:
Location: Exhibit Hall C
Poster number: P2-114
Details for the scientific symposium and interactive panel discussion are as follows:
Title: Enhanced Echocardiography: It’s What You Don’t See That Matters
Date and Time:
Location: Science and
DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms (see Indications and Important Safety Information below and find full Prescribing Information at www.definityimaging.com).1 DEFINITY is engineered to produce small and consistently sized durable microbubbles to fully evaluate the left ventricle.1 DEFINITY® has extensive safety experience and a consistent safety profile.2 Since its launch in 2001, more than 11 million echo studies have been performed with DEFINITY® and it is the most prescribed contrast agent in the U.S.3
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
Do not administer DEFINITY® to patients with known or suspected hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration.
In post marketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions, on www.definityimaging.com.
1 DEFINITY® (Package Insert),
2 Data on file,